ABOUT THIS EVENT

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative and convenient therapeutic products for patients with endocrine and orphan lung diseases, visits the Nasdaq MarketSite in Times Square. The company recently entered into an agreement to acquire V-Go^® wearable insulin delivery device from Zealand Pharma, currently commercializes the only inhaled ultra rapid-acting mealtime insulin in the United States with Afrezza^® (insulin human) Inhalation Powder, and is awaiting word this month from its partner United Therapeutics regarding an FDA decision on Tyvaso DPI^™.

In honor of the occasion, Michael Castagna, PharmD, Chief Executive Officer for MannKind Corporation rings the Opening Bell.